首页 > 最新文献

Therapeutic Advances in Infectious Disease最新文献

英文 中文
The impact of follow-up FDG-PET/CT on the management of focal infectious diseases: a retrospective cohort study. FDG-PET/CT随访对局灶性传染病管理的影响:一项回顾性队列研究
IF 3.4 Q2 INFECTIOUS DISEASES Pub Date : 2025-11-21 eCollection Date: 2025-01-01 DOI: 10.1177/20499361251391254
Badarne Mohammad, Kagna Olga, Keidar Zohar, Ghanem-Zoubi Nesrin

Background: The use of fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in the assessment of infectious diseases has been increasing, yet research on its impact during follow-up remains scarce.

Objectives: To evaluate the impact of follow-up FDG-PET/CT on managing focal infectious diseases.

Design: An observational, retrospective, single-center study.

Methods: Patients who underwent FDG-PET/CT for the diagnosis of focal infection and had a follow-up FDG-PET/CT between January 1, 2012 and October 31, 2023 were included. The impact of follow-up FDG-PET/CT on management was defined as findings leading to any change in antibiotic treatment or any source control interventions (impact group), which was compared to follow-up FDG-PET/CT that did not lead to any change in management (no-impact group).

Results: Eighty-nine patients were included, with a mean age of 62 ± 14.6 years. The most common infections were of skeletal (n = 34, 38.2%) and cardiovascular origin (n = 16, 17.9%). Overall, the follow-up FDG-PET/CT findings resulted in changing the management in 57 (64%) patients. It led to antibiotic change in 54 (60.7%) patients, and to source control intervention in 29 (32.6%) patients. Demographic and clinical characteristics of the impact group and the no-impact group were similar, except for a significantly higher rate of gram-positive bacteremia, which was detected in 26 (93%) patients with bacteremia in the impact group (mostly Staphylococcus aureus) compared to 8 (57%) of patients in the no-impact group, p = 0.01. Impact of FDG-PET/CT was associated with worsening clinical status, observed in 33 patients (57.9%) in the impact group compared to 6 (18.8%) in the no-impact group, p = 0.002.

Conclusion: Follow-up FDG-PET/CT appears to have a significant impact on managing selected patients with focal infections, particularly those caused by gram-positive bacteremia or with an unfavorable clinical course.

背景:氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG-PET/CT)在传染病评估中的应用越来越多,但对其在随访中的影响的研究仍然很少。目的:评价FDG-PET/CT随访对局灶性传染病治疗的影响。设计:一项观察性、回顾性、单中心研究。方法:选取2012年1月1日至2023年10月31日期间行FDG-PET/CT诊断局灶性感染并随访的患者。随访FDG-PET/CT对管理的影响定义为发现导致抗生素治疗或任何源头控制干预措施的任何变化(影响组),并将其与未导致管理任何变化的随访FDG-PET/CT(无影响组)进行比较。结果:89例患者入组,平均年龄62±14.6岁。最常见的感染是骨骼(n = 34, 38.2%)和心血管(n = 16, 17.9%)。总体而言,随访FDG-PET/CT结果改变了57例(64%)患者的治疗方法。导致54例(60.7%)患者改变抗生素,29例(32.6%)患者采取源头控制干预。冲击组和非冲击组的人口学和临床特征相似,除了革兰氏阳性菌血症的发生率明显更高,冲击组有26例(93%)的菌血症患者检测到革兰氏阳性菌血症(主要是金黄色葡萄球菌),而非冲击组有8例(57%),p = 0.01。FDG-PET/CT的影响与临床状况恶化有关,影响组有33例(57.9%)患者观察到,而无影响组有6例(18.8%)患者观察到,p = 0.002。结论:随访FDG-PET/CT似乎对管理选定的局灶性感染患者有重要影响,特别是那些由革兰氏阳性菌血症引起或临床病程不利的患者。
{"title":"The impact of follow-up FDG-PET/CT on the management of focal infectious diseases: a retrospective cohort study.","authors":"Badarne Mohammad, Kagna Olga, Keidar Zohar, Ghanem-Zoubi Nesrin","doi":"10.1177/20499361251391254","DOIUrl":"10.1177/20499361251391254","url":null,"abstract":"<p><strong>Background: </strong>The use of fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in the assessment of infectious diseases has been increasing, yet research on its impact during follow-up remains scarce.</p><p><strong>Objectives: </strong>To evaluate the impact of follow-up FDG-PET/CT on managing focal infectious diseases.</p><p><strong>Design: </strong>An observational, retrospective, single-center study.</p><p><strong>Methods: </strong>Patients who underwent FDG-PET/CT for the diagnosis of focal infection and had a follow-up FDG-PET/CT between January 1, 2012 and October 31, 2023 were included. The impact of follow-up FDG-PET/CT on management was defined as findings leading to any change in antibiotic treatment or any source control interventions (impact group), which was compared to follow-up FDG-PET/CT that did not lead to any change in management (no-impact group).</p><p><strong>Results: </strong>Eighty-nine patients were included, with a mean age of 62 ± 14.6 years. The most common infections were of skeletal (<i>n</i> = 34, 38.2%) and cardiovascular origin (<i>n</i> = 16, 17.9%). Overall, the follow-up FDG-PET/CT findings resulted in changing the management in 57 (64%) patients. It led to antibiotic change in 54 (60.7%) patients, and to source control intervention in 29 (32.6%) patients. Demographic and clinical characteristics of the impact group and the no-impact group were similar, except for a significantly higher rate of gram-positive bacteremia, which was detected in 26 (93%) patients with bacteremia in the impact group (mostly <i>Staphylococcus aureus</i>) compared to 8 (57%) of patients in the no-impact group, <i>p</i> = 0.01. Impact of FDG-PET/CT was associated with worsening clinical status, observed in 33 patients (57.9%) in the impact group compared to 6 (18.8%) in the no-impact group, <i>p</i> = 0.002.</p><p><strong>Conclusion: </strong>Follow-up FDG-PET/CT appears to have a significant impact on managing selected patients with focal infections, particularly those caused by gram-positive bacteremia or with an unfavorable clinical course.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251391254"},"PeriodicalIF":3.4,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12639224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145589544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review of non-antibiotic treatment and prevention of recurrent UTIs - a summary of current guidance and suggested treatment algorithm. 回顾非抗生素治疗和预防复发性尿路感染-目前的指导和建议的治疗算法的总结。
IF 3.4 Q2 INFECTIOUS DISEASES Pub Date : 2025-11-18 eCollection Date: 2025-01-01 DOI: 10.1177/20499361251395915
Amelia Simenacz, Vaki Antoniou, Bhaskar K Somani
{"title":"Review of non-antibiotic treatment and prevention of recurrent UTIs - a summary of current guidance and suggested treatment algorithm.","authors":"Amelia Simenacz, Vaki Antoniou, Bhaskar K Somani","doi":"10.1177/20499361251395915","DOIUrl":"10.1177/20499361251395915","url":null,"abstract":"","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251395915"},"PeriodicalIF":3.4,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12627364/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145565664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antibiotic impact on human microecology in low- and middle-income countries: a systematic age-stratified review of gut and respiratory microbiome and resistome. 抗生素对低收入和中等收入国家人类微生态的影响:对肠道和呼吸微生物组和抵抗组的系统年龄分层回顾。
IF 3.4 Q2 INFECTIOUS DISEASES Pub Date : 2025-11-14 eCollection Date: 2025-01-01 DOI: 10.1177/20499361251389738
Samuel Nee-Amugie Yartey, Aaron Awere-Duodu, Anastasia Akosua Asantewaa, Eric S Donkor

Background: Antibiotic exposure disrupts microbial communities in the gut and respiratory tract, causing functional changes that may have lasting health impacts and contribute to the spread of antibiotic resistance genes (ARGs) throughout life. However, age-stratified evidence of these effects, particularly in low- and middle-income countries (LMICs), remains limited.

Objective: This systematic review assessed the impact of antibiotics on gut and respiratory microbiomes and resistomes in LMICs, with separate analyses for adults and children.

Data sources: PubMed, Scopus, Web of Science, & ScienceDirect.

Methods: A comprehensive literature search was conducted using a predefined search strategy and eligibility criteria to identify relevant studies from LMICs. Twenty-five studies met the inclusion criteria: 23 examined the gut microbiome, and 2 focused on the respiratory microbiome. Key outcomes included microbial diversity (alpha/beta/gamma), taxonomic shifts, resistome profiles, functional changes, and recovery potentials, stratified by age group and body site.

Results: Antibiotic exposure was generally associated with reductions in microbial diversity and altered taxonomic composition, with children showing more pronounced and prolonged disruptions than adults. Analysis of resistome changes revealed a critical finding: while antibiotics consistently selected for ARGs matching the drug class administered, a substantial reservoir of non-matching, background ARGs, conferring resistance to beta-lactams, aminoglycosides, vancomycin, tetracyclines, was also highly prevalent across studies. This indicates a silent pre-existing resistome that is enriched by antibiotic pressure. ARGs were more abundant in adult resistomes, though functional changes occurred across age groups. Microbiome recovery was observed over time, but resistome recovery was limited.

Conclusion: Antibiotic use significantly disturbs the gut and respiratory microbiomes and promotes ARG enrichment, especially in children, who demonstrate greater susceptibility and lower recovery potential. These findings emphasise the need for targeted antibiotic stewardship, improved microbiome recovery research, and enhanced resistome monitoring in LMICs.

Trail registration: International Prospective Register of Systematic Reviews (PROSPERO), ID: CRD420250641394.

背景:抗生素暴露会破坏肠道和呼吸道中的微生物群落,导致可能对健康产生持久影响的功能变化,并有助于抗生素耐药基因(ARGs)在一生中的传播。然而,这些影响的年龄分层证据仍然有限,特别是在低收入和中等收入国家(LMICs)。目的:本系统综述评估了抗生素对低收入国家肠道和呼吸微生物组及抵抗组的影响,并对成人和儿童进行了单独分析。数据来源:PubMed, Scopus, Web of Science, & ScienceDirect。方法:使用预定义的检索策略和资格标准进行全面的文献检索,以确定中低收入国家的相关研究。25项研究符合纳入标准:23项研究检查肠道微生物组,2项研究关注呼吸微生物组。主要结果包括微生物多样性(α / β / γ)、分类变化、抵抗组谱、功能变化和恢复潜力,并按年龄组和身体部位分层。结果:抗生素暴露通常与微生物多样性减少和分类组成改变有关,儿童比成人表现出更明显和更持久的破坏。对抵抗组变化的分析揭示了一个重要的发现:尽管与所施用药物类别相匹配的ARGs始终选择抗生素,但在研究中也高度普遍存在大量不匹配的背景ARGs,这些ARGs赋予了对β -内酰胺类、氨基糖苷类、万古霉素、四环素类的耐药性。这表明一种沉默的预先存在的抵抗组在抗生素压力下变得丰富。ARGs在成人抵抗体中更为丰富,尽管在不同年龄组中发生了功能变化。随着时间的推移,观察到微生物组的恢复,但抵抗组的恢复有限。结论:抗生素使用明显扰乱肠道和呼吸道微生物群,促进ARG富集,特别是在儿童中,他们表现出更大的易感性和更低的恢复潜力。这些发现强调了中低收入国家需要有针对性的抗生素管理、改进微生物组恢复研究和加强耐药组监测。试验注册:国际前瞻性系统评价注册(PROSPERO), ID: CRD420250641394。
{"title":"Antibiotic impact on human microecology in low- and middle-income countries: a systematic age-stratified review of gut and respiratory microbiome and resistome.","authors":"Samuel Nee-Amugie Yartey, Aaron Awere-Duodu, Anastasia Akosua Asantewaa, Eric S Donkor","doi":"10.1177/20499361251389738","DOIUrl":"10.1177/20499361251389738","url":null,"abstract":"<p><strong>Background: </strong>Antibiotic exposure disrupts microbial communities in the gut and respiratory tract, causing functional changes that may have lasting health impacts and contribute to the spread of antibiotic resistance genes (ARGs) throughout life. However, age-stratified evidence of these effects, particularly in low- and middle-income countries (LMICs), remains limited.</p><p><strong>Objective: </strong>This systematic review assessed the impact of antibiotics on gut and respiratory microbiomes and resistomes in LMICs, with separate analyses for adults and children.</p><p><strong>Data sources: </strong>PubMed, Scopus, Web of Science, & ScienceDirect.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted using a predefined search strategy and eligibility criteria to identify relevant studies from LMICs. Twenty-five studies met the inclusion criteria: 23 examined the gut microbiome, and 2 focused on the respiratory microbiome. Key outcomes included microbial diversity (alpha/beta/gamma), taxonomic shifts, resistome profiles, functional changes, and recovery potentials, stratified by age group and body site.</p><p><strong>Results: </strong>Antibiotic exposure was generally associated with reductions in microbial diversity and altered taxonomic composition, with children showing more pronounced and prolonged disruptions than adults. Analysis of resistome changes revealed a critical finding: while antibiotics consistently selected for ARGs matching the drug class administered, a substantial reservoir of non-matching, background ARGs, conferring resistance to beta-lactams, aminoglycosides, vancomycin, tetracyclines, was also highly prevalent across studies. This indicates a silent pre-existing resistome that is enriched by antibiotic pressure. ARGs were more abundant in adult resistomes, though functional changes occurred across age groups. Microbiome recovery was observed over time, but resistome recovery was limited.</p><p><strong>Conclusion: </strong>Antibiotic use significantly disturbs the gut and respiratory microbiomes and promotes ARG enrichment, especially in children, who demonstrate greater susceptibility and lower recovery potential. These findings emphasise the need for targeted antibiotic stewardship, improved microbiome recovery research, and enhanced resistome monitoring in LMICs.</p><p><strong>Trail registration: </strong>International Prospective Register of Systematic Reviews (PROSPERO), ID: CRD420250641394.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251389738"},"PeriodicalIF":3.4,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12618827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145542975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of a multistep urinary tract infection-focused disease state stewardship initiative on the treatment of asymptomatic urinary presentations: a retrospective cohort study. 多步骤尿路感染疾病状态管理对无症状尿症状治疗的影响:一项回顾性队列研究
IF 3.4 Q2 INFECTIOUS DISEASES Pub Date : 2025-11-10 eCollection Date: 2025-01-01 DOI: 10.1177/20499361251391259
Christian Tyler Pitcock, Danielle Casaus, Sarah E Garvey, Katie Ruf, Donna R Burgess, Jeremy D VanHoose, David S Burgess, Ryan Mynatt, Armaghan-E-Rehman Mansoor, Nicholas Van Sickels, Mitu Karki Maskey, Thein Myint, Aric Schadler, Katie L Wallace

Background: Asymptomatic bacteriuria (ASB) is often overtreated, risking patient harm through unnecessary antimicrobial use and fostering antimicrobial resistance. Despite this, patients continue to be treated for ASB requiring targeted intervention for antimicrobial stewardship teams across health systems.

Objectives: This study assessed the impact of a multistep urinary tract infection (UTI)-focused stewardship initiative by comparing the incidence of asymptomatic urinary presentation (AUP) treatment before and after implementation.

Design: Retrospective cohort study.

Methods: Patients ⩾18 years at University of Kentucky HealthCare who received antimicrobial therapy with a urinalysis (UA) and/or urine culture (UCx) collected for a presumed UTI between January 2023 and March 2023 (pre-implementation) and January 2024 and March 2024 (post-implementation) were included in the study. Our primary outcome was to compare the frequency of AUP treatment between groups.

Results: Overall, 288 patients were included in the study, with 144 patients in both the pre- and post-implementation groups. Treatment of AUPs significantly decreased by 12% after initiative implementation (47% pre-implementation vs 35% post-implementation, p = 0.042). Additionally, we observed a significant difference in guideline-adherent management between the two groups (29% pre-implementation vs 44% post-implementation, p = 0.007). Patients were more likely to receive guideline-adherent UTI treatment durations (38% vs 53%, p = 0.009) and guideline-adherent definitive antibiotics (18% vs 35%, p < 0.001) post-implementation compared to pre-implementation.

Conclusion: Our stewardship initiative resulted in reduced treatment of AUPs and improved adherence to UTI management guidelines. Overall, a multifaceted stewardship initiative is a successful intervention to decrease the treatment of AUPs and unnecessary antibiotic utilization. However, additional frontline stewardship initiatives are likely warranted to decrease the unnecessary ordering of UAs.

背景:无症状细菌性尿症(ASB)经常被过度治疗,通过不必要的抗菌素使用和培养抗菌素耐药性,冒着患者伤害的风险。尽管如此,患者仍在接受ASB治疗,需要跨卫生系统的抗菌素管理团队进行有针对性的干预。目的:本研究通过比较实施前和实施后无症状尿表现(AUP)治疗的发生率,评估以多步骤尿路感染(UTI)为重点的管理倡议的影响。设计:回顾性队列研究。方法:在2023年1月至2023年3月(实施前)和2024年1月至2024年3月(实施后)之间为假定的UTI收集了尿液分析(UA)和/或尿液培养(UCx)并接受抗菌治疗的肯塔基大学医疗保健中心的未满18岁的患者被纳入研究。我们的主要结局是比较各组间AUP治疗的频率。结果:总的来说,288例患者被纳入研究,其中144例患者分别属于实施前和实施后组。主动实施后,aup的治疗显著减少了12%(实施前47% vs实施后35%,p = 0.042)。此外,我们观察到两组患者在指南依从性管理方面存在显著差异(实施前29% vs实施后44%,p = 0.007)。患者更有可能接受指南遵循的UTI治疗时间(38%对53%,p = 0.009)和指南遵循的最终抗生素(18%对35%,p)。结论:我们的管理倡议减少了aup的治疗,提高了对UTI管理指南的依从性。总的来说,一个多方面的管理倡议是一个成功的干预措施,以减少治疗aup和不必要的抗生素使用。然而,额外的一线管理措施可能有必要减少不必要的无人机订购。
{"title":"Impact of a multistep urinary tract infection-focused disease state stewardship initiative on the treatment of asymptomatic urinary presentations: a retrospective cohort study.","authors":"Christian Tyler Pitcock, Danielle Casaus, Sarah E Garvey, Katie Ruf, Donna R Burgess, Jeremy D VanHoose, David S Burgess, Ryan Mynatt, Armaghan-E-Rehman Mansoor, Nicholas Van Sickels, Mitu Karki Maskey, Thein Myint, Aric Schadler, Katie L Wallace","doi":"10.1177/20499361251391259","DOIUrl":"10.1177/20499361251391259","url":null,"abstract":"<p><strong>Background: </strong>Asymptomatic bacteriuria (ASB) is often overtreated, risking patient harm through unnecessary antimicrobial use and fostering antimicrobial resistance. Despite this, patients continue to be treated for ASB requiring targeted intervention for antimicrobial stewardship teams across health systems.</p><p><strong>Objectives: </strong>This study assessed the impact of a multistep urinary tract infection (UTI)-focused stewardship initiative by comparing the incidence of asymptomatic urinary presentation (AUP) treatment before and after implementation.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Methods: </strong>Patients ⩾18 years at University of Kentucky HealthCare who received antimicrobial therapy with a urinalysis (UA) and/or urine culture (UCx) collected for a presumed UTI between January 2023 and March 2023 (pre-implementation) and January 2024 and March 2024 (post-implementation) were included in the study. Our primary outcome was to compare the frequency of AUP treatment between groups.</p><p><strong>Results: </strong>Overall, 288 patients were included in the study, with 144 patients in both the pre- and post-implementation groups. Treatment of AUPs significantly decreased by 12% after initiative implementation (47% pre-implementation vs 35% post-implementation, <i>p</i> = 0.042). Additionally, we observed a significant difference in guideline-adherent management between the two groups (29% pre-implementation vs 44% post-implementation, <i>p</i> = 0.007). Patients were more likely to receive guideline-adherent UTI treatment durations (38% vs 53%, <i>p</i> = 0.009) and guideline-adherent definitive antibiotics (18% vs 35%, <i>p</i> < 0.001) post-implementation compared to pre-implementation.</p><p><strong>Conclusion: </strong>Our stewardship initiative resulted in reduced treatment of AUPs and improved adherence to UTI management guidelines. Overall, a multifaceted stewardship initiative is a successful intervention to decrease the treatment of AUPs and unnecessary antibiotic utilization. However, additional frontline stewardship initiatives are likely warranted to decrease the unnecessary ordering of UAs.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251391259"},"PeriodicalIF":3.4,"publicationDate":"2025-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12602917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145507586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Entomo-virological surveillance of arboviruses in the Americas: prospects for the use of paper-based nucleic acid stabilization materials. 美洲虫媒病毒的虫媒病毒学监测:使用纸质核酸稳定材料的前景。
IF 3.4 Q2 INFECTIOUS DISEASES Pub Date : 2025-11-01 eCollection Date: 2025-01-01 DOI: 10.1177/20499361251391261
Rosana Pérez-Franco, Daniel B Ramírez-Osorio, Joel Monroy-Carreño, Marlen Martínez-Gutiérrez, Gabriel Parra-Henao, Jose A Usme-Ciro

Arthropod-borne viruses (arboviruses) represent a major public health burden for people living or visiting tropical and subtropical countries, where an endemic/epidemic cycle has been successfully established for Orthoflavivirus denguei, Alphavirus chikungunya, and O. zikaense. The risk for the reemergence of other viruses in the urban cycle in the Americas, such as A. mayaro and O. flavi is also of major concern, which justifies the intensification of active surveillance in urban, rural, and sylvatic areas to determine the virus activity in different settings. Entomological surveillance consists mainly of collecting, identifying, and estimating the relative densities of the main disease-transmitting vector species, and more recently, estimating infection rates for the more relevant pathogens. The new approaches for monitoring arthropod vectors of medical importance pose new challenges, including maintaining the cold chain to preserve the pathogen infectivity or nucleic acid stability, especially for RNA genomes, such as those of the main arboviruses. Hence, alternatives such as mosquito traps equipped with solid-phase materials impregnated with honey baits for mosquito feeding, saliva expectoration, and nucleic acid stabilization have been gaining popularity as they can be used as an early warning system to provide arbovirus genetic information useful in molecular epidemiology studies. Here, we present the state of the art in the use of this approach and highlight the need for exploration of the potential of different available solid-phase materials for nucleic acid immobilization and stabilization during mosquito feeding on honey-baited traps. The current challenges for the successful implementation of feasible entomo-virological surveillance as a routine arbovirus surveillance tool in mosquitoes in urban and rural settings of endemic areas are also discussed.

节肢动物传播的病毒(虫媒病毒)是生活或访问热带和亚热带国家的人们的主要公共卫生负担,这些国家已成功建立了登革热正黄病毒、基孔肯雅甲病毒和寨卡热鄂病毒的流行/流行周期。在美洲的城市循环中再次出现其他病毒(如马雅罗弧菌和黄弧菌)的风险也令人严重关切,因此有理由在城市、农村和森林地区加强主动监测,以确定不同环境下的病毒活动。昆虫学监测主要包括收集、识别和估计主要疾病传播媒介物种的相对密度,最近还包括估计更相关病原体的感染率。监测具有医学重要性的节肢动物媒介的新方法提出了新的挑战,包括维持冷链以保持病原体传染性或核酸稳定性,特别是对于RNA基因组,例如主要虫媒病毒的基因组。因此,诸如配备有蜂蜜诱饵的固相材料的蚊虫诱捕器,用于蚊子喂养,唾液分泌和核酸稳定等替代方法已经越来越受欢迎,因为它们可以作为早期预警系统,为分子流行病学研究提供有用的虫媒病毒遗传信息。在这里,我们介绍了使用这种方法的最新技术,并强调需要探索不同可用固相材料在蚊子在蜂蜜诱捕器上进食期间用于核酸固定和稳定的潜力。本文还讨论了目前在流行地区的城市和农村环境中成功实施可行的昆虫病毒学监测作为常规虫媒病毒监测工具所面临的挑战。
{"title":"Entomo-virological surveillance of arboviruses in the Americas: prospects for the use of paper-based nucleic acid stabilization materials.","authors":"Rosana Pérez-Franco, Daniel B Ramírez-Osorio, Joel Monroy-Carreño, Marlen Martínez-Gutiérrez, Gabriel Parra-Henao, Jose A Usme-Ciro","doi":"10.1177/20499361251391261","DOIUrl":"10.1177/20499361251391261","url":null,"abstract":"<p><p>Arthropod-borne viruses (arboviruses) represent a major public health burden for people living or visiting tropical and subtropical countries, where an endemic/epidemic cycle has been successfully established for <i>Orthoflavivirus denguei</i>, <i>Alphavirus chikungunya</i>, and <i>O. zikaense</i>. The risk for the reemergence of other viruses in the urban cycle in the Americas, such as <i>A. mayaro</i> and <i>O. flavi</i> is also of major concern, which justifies the intensification of active surveillance in urban, rural, and sylvatic areas to determine the virus activity in different settings. Entomological surveillance consists mainly of collecting, identifying, and estimating the relative densities of the main disease-transmitting vector species, and more recently, estimating infection rates for the more relevant pathogens. The new approaches for monitoring arthropod vectors of medical importance pose new challenges, including maintaining the cold chain to preserve the pathogen infectivity or nucleic acid stability, especially for RNA genomes, such as those of the main arboviruses. Hence, alternatives such as mosquito traps equipped with solid-phase materials impregnated with honey baits for mosquito feeding, saliva expectoration, and nucleic acid stabilization have been gaining popularity as they can be used as an early warning system to provide arbovirus genetic information useful in molecular epidemiology studies. Here, we present the state of the art in the use of this approach and highlight the need for exploration of the potential of different available solid-phase materials for nucleic acid immobilization and stabilization during mosquito feeding on honey-baited traps. The current challenges for the successful implementation of feasible entomo-virological surveillance as a routine arbovirus surveillance tool in mosquitoes in urban and rural settings of endemic areas are also discussed.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251391261"},"PeriodicalIF":3.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12580509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145446103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resistance mechanisms and therapeutic strategies for Pseudomonas aeruginosa infections. 铜绿假单胞菌感染的耐药机制及治疗策略。
IF 3.4 Q2 INFECTIOUS DISEASES Pub Date : 2025-10-29 eCollection Date: 2025-01-01 DOI: 10.1177/20499361251388382
Georgios Meletis, Elena Karastergiou

Pseudomonas aeruginosa is one of the most clinically important Gram-negative bacteria and is related to many severe and life-threatening infections worldwide. It presents intrinsic resistance against many antibiotics and has the ability to acquire or develop additional mechanisms to overcome the action of all anti-pseudomonal drugs. Formerly abandoned antibiotics and new compounds such as cefiderocol and combinations of β-lactams with new β-lactamase inhibitors are considered for the treatment of infections due to multi- or extensively-drug-resistant strains. In the present review, the antimicrobial resistance mechanisms of P. aeruginosa and the potential treatment options for the difficult to treat P. aeruginosa infections are discussed in an attempt to correlate microbiological and laboratory data to the choice of optimal treatment in everyday clinical practice.

铜绿假单胞菌是临床上最重要的革兰氏阴性菌之一,在世界范围内与许多严重和危及生命的感染有关。它表现出对许多抗生素的内在耐药性,并有能力获得或发展额外的机制来克服所有抗假单胞菌药物的作用。以前废弃的抗生素和新的化合物,如头孢地罗,以及β-内酰胺类药物与新的β-内酰胺酶抑制剂的组合,被考虑用于治疗多重或广泛耐药菌株引起的感染。在本综述中,本文讨论了铜绿假单胞菌的耐药机制和难以治疗的铜绿假单胞菌感染的潜在治疗方案,试图将微生物学和实验室数据与日常临床实践中最佳治疗方案的选择联系起来。
{"title":"Resistance mechanisms and therapeutic strategies for <i>Pseudomonas aeruginosa</i> infections.","authors":"Georgios Meletis, Elena Karastergiou","doi":"10.1177/20499361251388382","DOIUrl":"10.1177/20499361251388382","url":null,"abstract":"<p><p><i>Pseudomonas aeruginosa</i> is one of the most clinically important Gram-negative bacteria and is related to many severe and life-threatening infections worldwide. It presents intrinsic resistance against many antibiotics and has the ability to acquire or develop additional mechanisms to overcome the action of all anti-pseudomonal drugs. Formerly abandoned antibiotics and new compounds such as cefiderocol and combinations of β-lactams with new β-lactamase inhibitors are considered for the treatment of infections due to multi- or extensively-drug-resistant strains. In the present review, the antimicrobial resistance mechanisms of <i>P. aeruginosa</i> and the potential treatment options for the difficult to treat <i>P. aeruginosa</i> infections are discussed in an attempt to correlate microbiological and laboratory data to the choice of optimal treatment in everyday clinical practice.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251388382"},"PeriodicalIF":3.4,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12576158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145432537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of meteorological variables on Salmonella bacteraemia in Mysuru District, Karnataka State, India: a retrospective time-series analysis. 气象变量对印度卡纳塔克邦Mysuru地区沙门氏菌血症的影响:回顾性时间序列分析。
IF 3.4 Q2 INFECTIOUS DISEASES Pub Date : 2025-10-27 eCollection Date: 2025-01-01 DOI: 10.1177/20499361251389056
Naveen Manchal, Mahadevaiah N Sumana, Megan K Young, Maria Eugenia Castellanos, Peter Leggat, Oyelola A Adegboye

Background: Salmonella species are major pathogens responsible for gastroenteritis and typhoid fever. In 2017, Salmonella enterocolitis caused over 95 million cases of diarrhoea and 50,000 deaths globally, with India bearing more than 50% of the typhoid burden.

Objectives: To test the association of monthly mean and maximum temperature, precipitation and absolute humidity with the incidence of Salmonella bacteraemia in a metropolitan city in South India.

Design: A retrospective time-series analysis.

Methods: This study employed a retrospective time-series analysis to evaluate the influence of meteorological variables, including temperature, absolute humidity and precipitation, on Salmonella bacteraemia in a metropolitan city in South India.

Results: Between 2014 and 2019, a total of 492 blood culture-confirmed cases of Salmonella bacteraemia were identified in Mysuru, India. S. typhi was predominantly among younger patients, while non-typhoidal Salmonella was more frequent in older age groups. Resistance was highest to nalidixic acid (84%), with a rising trend in ciprofloxacin resistance. Increased mean temperature (lags 1-3 months) and absolute humidity were positively associated with Salmonella bacteraemia, while temperature variability was protective, and monsoon rainfall significantly increased the risk. Cumulative exposure-response analyses further showed elevated risks at higher humidity (>26 g/m³), temperatures (>34°C) and extreme precipitation (>250 mm), although confidence intervals were wide and most associations did not reach statistical significance.

Conclusion: This single-centre retrospective time-series analysis has demonstrated that meteorological variables impact the incidence of Salmonella bacteraemia, which could lead to increased antibiotic use and contribute to the development of resistance.

背景:沙门氏菌是引起肠胃炎和伤寒的主要病原体。2017年,沙门氏菌肠结肠炎在全球造成9500多万例腹泻病例和5万例死亡,其中印度承担了50%以上的伤寒负担。目的:研究印度南部某大城市月平均和最高气温、降水量和绝对湿度与沙门氏菌血症发病率的关系。设计:回顾性时间序列分析。方法:本研究采用回顾性时间序列分析,评估气象变量,包括温度、绝对湿度和降水,对沙门氏菌血症在印度南部一个大城市的影响。结果:2014年至2019年,印度迈苏尔共发现492例经血培养确诊的沙门氏菌血症病例。伤寒沙门氏菌在年轻患者中占主导地位,而非伤寒沙门氏菌在老年人群中更为常见。对萘啶酸的耐药率最高(84%),对环丙沙星的耐药率呈上升趋势。升高的平均温度(滞后1-3个月)和绝对湿度与沙门氏菌血症呈正相关,而温度变化具有保护作用,季风降雨显著增加了风险。累积暴露响应分析进一步表明,在较高湿度(>26 g/m³)、较高温度(>34°C)和极端降水(>250 mm)下,风险升高,尽管置信区间很宽,大多数关联没有达到统计学意义。结论:这项单中心回顾性时间序列分析表明,气象变量影响沙门氏菌菌血症的发病率,这可能导致抗生素使用增加,并促进耐药性的发展。
{"title":"The impact of meteorological variables on <i>Salmonella</i> bacteraemia in Mysuru District, Karnataka State, India: a retrospective time-series analysis.","authors":"Naveen Manchal, Mahadevaiah N Sumana, Megan K Young, Maria Eugenia Castellanos, Peter Leggat, Oyelola A Adegboye","doi":"10.1177/20499361251389056","DOIUrl":"10.1177/20499361251389056","url":null,"abstract":"<p><strong>Background: </strong><i>Salmonella</i> species are major pathogens responsible for gastroenteritis and typhoid fever. In 2017, <i>Salmonella enterocolitis</i> caused over 95 million cases of diarrhoea and 50,000 deaths globally, with India bearing more than 50% of the typhoid burden.</p><p><strong>Objectives: </strong>To test the association of monthly mean and maximum temperature, precipitation and absolute humidity with the incidence of <i>Salmonella</i> bacteraemia in a metropolitan city in South India.</p><p><strong>Design: </strong>A retrospective time-series analysis.</p><p><strong>Methods: </strong>This study employed a retrospective time-series analysis to evaluate the influence of meteorological variables, including temperature, absolute humidity and precipitation, on <i>Salmonella</i> bacteraemia in a metropolitan city in South India.</p><p><strong>Results: </strong>Between 2014 and 2019, a total of 492 blood culture-confirmed cases of <i>Salmonella</i> bacteraemia were identified in Mysuru, India. <i>S. typhi</i> was predominantly among younger patients, while non-typhoidal <i>Salmonella</i> was more frequent in older age groups. Resistance was highest to nalidixic acid (84%), with a rising trend in ciprofloxacin resistance. Increased mean temperature (lags 1-3 months) and absolute humidity were positively associated with <i>Salmonella</i> bacteraemia, while temperature variability was protective, and monsoon rainfall significantly increased the risk. Cumulative exposure-response analyses further showed elevated risks at higher humidity (>26 g/m³), temperatures (>34°C) and extreme precipitation (>250 mm), although confidence intervals were wide and most associations did not reach statistical significance.</p><p><strong>Conclusion: </strong>This single-centre retrospective time-series analysis has demonstrated that meteorological variables impact the incidence of <i>Salmonella</i> bacteraemia, which could lead to increased antibiotic use and contribute to the development of resistance.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251389056"},"PeriodicalIF":3.4,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12575929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145432548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative effectiveness of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a systematic review of observational studies. 头孢唑林与抗葡萄球菌青霉素治疗甲氧西林敏感金黄色葡萄球菌感染性心内膜炎的比较疗效:一项观察性研究的系统综述。
IF 3.4 Q2 INFECTIOUS DISEASES Pub Date : 2025-10-27 eCollection Date: 2025-01-01 DOI: 10.1177/20499361251384146
Laura Juliana Jaime-Ardila, Jorge Leonardo Támara-Rivera, Laura Cristina Nocua-Báez, Candida Díaz-Brochero, Sugeich Del Mar Melendez-Rhenals

Background: Methicillin-susceptible Staphylococcus aureus (MSSA) is a leading cause of infective endocarditis (IE), associated with high morbidity and mortality. While antistaphylococcal penicillins (ASPs) are considered the standard treatment, cefazolin has emerged as a potential alternative due to its pharmacokinetic advantages and lower toxicity profile.

Objectives: To assess the efficacy and safety of cefazolin compared with ASPs in adult patients with MSSA infective endocarditis.

Design: Systematic review and meta-analysis.

Data sources and methods: We systematically searched MEDLINE, Embase, CENTRAL, Scopus, and Web of Science up to 2024. We included cohort studies and non-randomized trials comparing cefazolin and ASPs in adult patients with MSSA IE. Risk of bias was evaluated using the ROBINS-I tool. Meta-analyses were performed using random-effects models to estimate pooled odds ratios (ORs) and standardized mean differences (SMDs).

Results: Seven cohort studies involving 1685 patients (305 cefazolin; 1380 ASPs) were included. Thirty-day mortality, reported in two studies (n = 1083), was lower with cefazolin (OR 0.49; 95% CI 0.29-0.83; I² = 0%). Ninety-day mortality (three studies, n = 475) showed no significant difference (OR 1.00; 95% CI 0.63-1.57; I² = 0%). No significant differences were observed in relapse rates (OR 1.01; 95% CI 0.34-3.02; I² = 12.5%), hospital stay duration (SMD -0.06; 95% CI -0.27 to 0.14), or bacteremia duration (SMD -0.96; 95% CI -1.93 to 0.01). Safety data suggested a lower incidence of adverse events with cefazolin, although definitions varied across studies. Risk of bias was moderate in most studies.

Conclusion: Cefazolin demonstrated comparable efficacy to ASPs for the treatment of MSSA IE, with a potential reduction in short-term mortality and a favorable safety profile. These findings support cefazolin as a viable therapeutic alternative, but randomized controlled trials are needed to confirm its effectiveness and safety.

Trial registration: PROSPERO registration number: CRD42024593515.

背景:甲氧西林敏感金黄色葡萄球菌(MSSA)是感染性心内膜炎(IE)的主要病因,具有较高的发病率和死亡率。虽然抗葡萄球菌青霉素(asp)被认为是标准治疗,但头孢唑林由于其药代动力学优势和较低的毒性,已成为一种潜在的替代方案。目的:比较头孢唑林与asp治疗成人msa感染性心内膜炎的疗效和安全性。设计:系统回顾和荟萃分析。数据来源和方法:系统检索MEDLINE、Embase、CENTRAL、Scopus和Web of Science,检索时间截止到2024年。我们纳入了队列研究和非随机试验,比较头孢唑林和asp在成年MSSA IE患者中的作用。使用ROBINS-I工具评估偏倚风险。采用随机效应模型进行meta分析,以估计合并优势比(ORs)和标准化平均差异(SMDs)。结果:纳入了7项队列研究,涉及1685例患者(305例头孢唑林;1380例asp)。在两项研究(n = 1083)中,头孢唑林的30天死亡率较低(OR 0.49; 95% CI 0.29-0.83; I²= 0%)。90天死亡率(3项研究,n = 475)无显著差异(OR 1.00; 95% CI 0.63-1.57; I²= 0%)。复发率(OR 1.01; 95% CI 0.34-3.02; I²= 12.5%)、住院时间(SMD -0.06; 95% CI -0.27 - 0.14)或菌血症持续时间(SMD -0.96; 95% CI -1.93 - 0.01)均无显著差异。安全性数据表明头孢唑林的不良事件发生率较低,尽管不同研究的定义不同。大多数研究的偏倚风险为中等。结论:头孢唑林在治疗MSSA IE方面表现出与asp相当的疗效,具有潜在的短期死亡率降低和良好的安全性。这些发现支持头孢唑林作为一种可行的治疗选择,但需要随机对照试验来证实其有效性和安全性。试验注册:普洛斯彼罗注册号:CRD42024593515。
{"title":"Comparative effectiveness of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a systematic review of observational studies.","authors":"Laura Juliana Jaime-Ardila, Jorge Leonardo Támara-Rivera, Laura Cristina Nocua-Báez, Candida Díaz-Brochero, Sugeich Del Mar Melendez-Rhenals","doi":"10.1177/20499361251384146","DOIUrl":"10.1177/20499361251384146","url":null,"abstract":"<p><strong>Background: </strong>Methicillin-susceptible <i>Staphylococcus aureus</i> (MSSA) is a leading cause of infective endocarditis (IE), associated with high morbidity and mortality. While antistaphylococcal penicillins (ASPs) are considered the standard treatment, cefazolin has emerged as a potential alternative due to its pharmacokinetic advantages and lower toxicity profile.</p><p><strong>Objectives: </strong>To assess the efficacy and safety of cefazolin compared with ASPs in adult patients with MSSA infective endocarditis.</p><p><strong>Design: </strong>Systematic review and meta-analysis.</p><p><strong>Data sources and methods: </strong>We systematically searched MEDLINE, Embase, CENTRAL, Scopus, and Web of Science up to 2024. We included cohort studies and non-randomized trials comparing cefazolin and ASPs in adult patients with MSSA IE. Risk of bias was evaluated using the ROBINS-I tool. Meta-analyses were performed using random-effects models to estimate pooled odds ratios (ORs) and standardized mean differences (SMDs).</p><p><strong>Results: </strong>Seven cohort studies involving 1685 patients (305 cefazolin; 1380 ASPs) were included. Thirty-day mortality, reported in two studies (<i>n</i> = 1083), was lower with cefazolin (OR 0.49; 95% CI 0.29-0.83; <i>I</i>² = 0%). Ninety-day mortality (three studies, <i>n</i> = 475) showed no significant difference (OR 1.00; 95% CI 0.63-1.57; <i>I</i>² = 0%). No significant differences were observed in relapse rates (OR 1.01; 95% CI 0.34-3.02; <i>I</i>² = 12.5%), hospital stay duration (SMD -0.06; 95% CI -0.27 to 0.14), or bacteremia duration (SMD -0.96; 95% CI -1.93 to 0.01). Safety data suggested a lower incidence of adverse events with cefazolin, although definitions varied across studies. Risk of bias was moderate in most studies.</p><p><strong>Conclusion: </strong>Cefazolin demonstrated comparable efficacy to ASPs for the treatment of MSSA IE, with a potential reduction in short-term mortality and a favorable safety profile. These findings support cefazolin as a viable therapeutic alternative, but randomized controlled trials are needed to confirm its effectiveness and safety.</p><p><strong>Trial registration: </strong>PROSPERO registration number: CRD42024593515.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251384146"},"PeriodicalIF":3.4,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12575952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145432603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic accuracy of the novel and biosafe molecular assay Orange G3 TBC compared to GeneXpert for tuberculosis diagnosis in resource-limited settings. 在资源有限的环境下,与GeneXpert相比,新型生物安全分子检测Orange G3 TBC在结核病诊断中的诊断准确性
IF 3.4 Q2 INFECTIOUS DISEASES Pub Date : 2025-10-21 eCollection Date: 2025-01-01 DOI: 10.1177/20499361251386681
Juan Carlos Garberi, Gabriel Estryk, Richard Chiara, Patricia Callisperis, Patricia Loza, Luis Scigliano, Sandra Andrea Casevecchie, Juan Ezequiel Garberi, Edgar Villarte, Mike Acevedo, Mónica Castro, Guadalupe Calvo Quiroz, Alex Huarachi, Leydi Martinez, Lucia Langer, Luis Prieto-Valiente, Mitchell Liester, Carlos Franco-Paredes, Pierre Kory

Background: Tuberculosis (TB) remains a global public health priority, with 10.5 million new cases and 1.5 million deaths reported in 2023. Current diagnostic methods face limitations in sensitivity, biosafety, and accessibility, particularly in low-resource settings.

Objective: This study evaluates the diagnostic accuracy of a novel, Polymerase Chain Reaction (PCR) platform (Orange G3 TBC), comparing it with the WHO-endorsed GeneXpert Ultra system in Oruro, Bolivia.

Design: We conducted a randomized, double-blind study.

Methods: The study included 71 clinical samples (67 sputum samples and 4 cerebrospinal fluid samples) from patients with presumptive TB. All samples were tested with GeneXpert Ultra and the Orange G3 TBC platform, which incorporates a unique biosafe processing system. Statistical analysis included sensitivity, specificity, predictive values (positive predictive value (PPV) and negative predictive value (NPV)), likelihood ratios (LR+ and LR-), and correlation measures.

Results: Orange G3 TBC demonstrated strong performance metrics compared to GeneXpert Ultra: sensitivity = 90%, specificity = 97%, diagnostic efficiency = 96%, PPV = 82%, and NPV = 98%. Statistical analysis showed a high correlation between the two methods (Pearson's correlation = 0.834, Kappa = 0.832, LR+ = 27.3, LR- = 0.103).

Conclusion: The Orange G3 TBC platform offers comparable diagnostic accuracy to GeneXpert Ultra. The system is adaptable to resource-limited settings, making it a viable alternative for TB diagnosis in endemic regions.

背景:结核病仍然是全球公共卫生优先事项,2023年报告的新病例为1050万例,死亡人数为150万。目前的诊断方法在敏感性、生物安全性和可及性方面存在局限性,特别是在资源匮乏的环境中。目的:本研究评估一种新型聚合酶链反应(PCR)平台(Orange G3 TBC)的诊断准确性,并将其与世卫组织认可的玻利维亚Oruro的GeneXpert Ultra系统进行比较。设计:我们进行了一项随机、双盲研究。方法:对71例推定结核患者临床标本(痰液标本67例,脑脊液标本4例)进行分析。所有样品均使用GeneXpert Ultra和Orange G3 TBC平台进行测试,该平台采用独特的生物安全处理系统。统计分析包括敏感性、特异性、预测值(阳性预测值(PPV)和阴性预测值(NPV)、似然比(LR+和LR-)以及相关指标。结果:与GeneXpert Ultra相比,Orange G3 TBC表现出强大的性能指标:敏感性= 90%,特异性= 97%,诊断效率= 96%,PPV = 82%, NPV = 98%。统计学分析显示,两种方法具有较高的相关性(Pearson’s correlation = 0.834, Kappa = 0.832, LR+ = 27.3, LR- = 0.103)。结论:Orange G3 TBC平台的诊断准确性与GeneXpert Ultra相当。该系统适用于资源有限的环境,使其成为流行地区结核病诊断的可行替代方案。
{"title":"Diagnostic accuracy of the novel and biosafe molecular assay Orange G3 TBC compared to GeneXpert for tuberculosis diagnosis in resource-limited settings.","authors":"Juan Carlos Garberi, Gabriel Estryk, Richard Chiara, Patricia Callisperis, Patricia Loza, Luis Scigliano, Sandra Andrea Casevecchie, Juan Ezequiel Garberi, Edgar Villarte, Mike Acevedo, Mónica Castro, Guadalupe Calvo Quiroz, Alex Huarachi, Leydi Martinez, Lucia Langer, Luis Prieto-Valiente, Mitchell Liester, Carlos Franco-Paredes, Pierre Kory","doi":"10.1177/20499361251386681","DOIUrl":"10.1177/20499361251386681","url":null,"abstract":"<p><strong>Background: </strong>Tuberculosis (TB) remains a global public health priority, with 10.5 million new cases and 1.5 million deaths reported in 2023. Current diagnostic methods face limitations in sensitivity, biosafety, and accessibility, particularly in low-resource settings.</p><p><strong>Objective: </strong>This study evaluates the diagnostic accuracy of a novel, Polymerase Chain Reaction (PCR) platform (Orange G3 TBC), comparing it with the WHO-endorsed GeneXpert Ultra system in Oruro, Bolivia.</p><p><strong>Design: </strong>We conducted a randomized, double-blind study.</p><p><strong>Methods: </strong>The study included 71 clinical samples (67 sputum samples and 4 cerebrospinal fluid samples) from patients with presumptive TB. All samples were tested with GeneXpert Ultra and the Orange G3 TBC platform, which incorporates a unique biosafe processing system. Statistical analysis included sensitivity, specificity, predictive values (positive predictive value (PPV) and negative predictive value (NPV)), likelihood ratios (LR+ and LR-), and correlation measures.</p><p><strong>Results: </strong>Orange G3 TBC demonstrated strong performance metrics compared to GeneXpert Ultra: sensitivity = 90%, specificity = 97%, diagnostic efficiency = 96%, PPV = 82%, and NPV = 98%. Statistical analysis showed a high correlation between the two methods (Pearson's correlation = 0.834, Kappa = 0.832, LR+ = 27.3, LR- = 0.103).</p><p><strong>Conclusion: </strong>The Orange G3 TBC platform offers comparable diagnostic accuracy to GeneXpert Ultra. The system is adaptable to resource-limited settings, making it a viable alternative for TB diagnosis in endemic regions.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251386681"},"PeriodicalIF":3.4,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12553880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145379170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children and Adolescents from 2003 to 2023: a Plain Language Summary of Publication. 2003年至2023年儿童和青少年减毒活疫苗和灭活疫苗的实际有效性:出版物的简明语言摘要。
IF 3.4 Q2 INFECTIOUS DISEASES Pub Date : 2025-10-17 eCollection Date: 2025-01-01 DOI: 10.1177/20499361251390680
Anke L Stuurman, Joshua Enxing, Aura V Gutiérrez, Christen M Gray, Ingrid T Sepúlveda-Pachón, Egbe Ubamadu, Allyn Bandell, Sylvia Taylor, Georges El Azzi, Wilhelmine Meeraus
<p><p>What is this summary about? This is a plain language summary describing the results of a systematic literature review and meta-analysis originally published in <i>Expert Review of Vaccines</i> in July 2025. Children and adolescents are an important group for <b>influenza</b> <b>vaccination</b> because they play a major role in spreading <b>influenza</b> viruses to others and are often hospitalized due to <b>influenza</b>. <b>Live attenuated influenza vaccines (LAIV)</b> and <b>inactivated <b>influenza</b> vaccines (IIV)</b> are two different types of <b>influenza</b> <b>vaccine</b> that are used to protect children and adolescents from <b>influenza</b> illness. This review looked at how well LAIV and IIV provided protection against <b>influenza</b> between 2003 (when LAIV was first available) and 2023 in children and adolescents under 18 years of age. Why was this review done? <b>Influenza</b> viruses can change rapidly in ways that affect how well vaccines work in a particular <b><b>influenza</b> season</b>. When this happens, <b>influenza</b> vaccines may not provide good protection because they take many months to produce, with development starting about 6 months before the <b>influenza</b> season begins. The specific versions of <b>influenza</b> viruses, or strains, used to make vaccines change from year to year based on recommendations from <b>The World Health Organization</b>. Public health bodies such as the United States' 'Advisory Committee on Immunization Practices' (US ACIP) and the United Kingdom's 'Joint Committee on <b>Vaccination</b> and Immunisation' also publish recommendations on which vaccines should be used for the upcoming <b>influenza</b> season on their respective websites and will update these recommendations for the next <b>influenza</b> season if studies show that a particular <b>vaccine</b> isn't providing enough protection. For this reason, <b>influenza</b> vaccines can lose their recommendation for use or other vaccines may be recommended instead for use in select groups. For example, the US ACIP stopped recommending LAIV for the 2016-17 and 2017-18 <b>influenza</b> seasons after some US-based studies showed it didn't protect well against the <b>influenza</b> A (H1N1) <b>virus</b> following the 2009 <b>influenza</b> A (H1N1) pandemic. However, an updated LAIV was developed that improved on the <b>strain selection</b> process and contained a replacement <b>influenza</b> A (H1N1) strain. This led to LAIV being recommended by the committee again for the 2018-2019 <b>influenza</b> season, and LAIV has continued to be recommended by the committee in its seasonal <b>vaccine</b> guidance each year since 2019. The researchers carried out this review to look at how well LAIV and IIV protected against <b>influenza</b> in children and adolescents in <b>real-world settings</b> (e.g. outside clinical trials) since LAIV was first approved in 2003. How was this review carried out? The researchers found studies of LAIV and IIV
这个总结是关于什么的?这是一份简明的语言摘要,描述了一项系统性文献综述和荟萃分析的结果,该结果最初发表于2025年7月的《疫苗专家评论》。儿童和青少年是接种流感疫苗的重要群体,因为他们在将流感病毒传播给他人方面发挥着重要作用,并经常因流感住院。流感减毒活疫苗(LAIV)和流感灭活疫苗(IIV)是两种不同类型的流感疫苗,用于保护儿童和青少年免受流感疾病的侵害。本综述研究了2003年(LAIV首次上市)至2023年间,LAIV和iv在18岁以下儿童和青少年中预防流感的效果。为什么要做这个综述?流感病毒可以迅速变化,从而影响疫苗在特定流感季节的效果。当这种情况发生时,流感疫苗可能无法提供良好的保护,因为它们需要许多个月的时间来生产,在流感季节开始前大约6个月开始开发。根据世界卫生组织的建议,用于制造疫苗的流感病毒或菌株的特定版本每年都在变化。公共卫生机构,如美国的“免疫实践咨询委员会”(US ACIP)和英国的“疫苗接种和免疫联合委员会”,也在各自的网站上公布了在即将到来的流感季节应该使用哪些疫苗的建议,如果研究表明某种疫苗不能提供足够的保护,将在下一个流感季节更新这些建议。因此,流感疫苗可能会失去推荐使用的资格,或者可能会建议在特定人群中使用其他疫苗。例如,在美国的一些研究表明LAIV在2009年甲型H1N1流感大流行后不能很好地预防甲型H1N1流感病毒后,美国ACIP停止推荐在2016-17和2017-18流感季节使用LAIV。然而,开发了一种更新的LAIV,改进了毒株选择过程,并包含替代甲型H1N1流感毒株。这导致该委员会在2018-2019年流感季节再次推荐LAIV,自2019年以来,该委员会每年在其季节性疫苗指南中继续推荐LAIV。这组科学家进行这一综述是为了观察自2003年LAIV首次获得批准以来,LAIV和iv在现实环境中(例如临床试验之外)对儿童和青少年预防流感的效果。这次审查是如何进行的?这组科学家找到了发表在科学期刊或公共卫生机构上的关于LAIV和iv疫苗有效性(VE)的研究,并对结果进行了筛选,只包括符合预先确定的研究设计和质量标准的研究。根据甲型H1N1流感和LAIV的历史,对每个流感季节和三个时间段的结果进行了检查,以了解LAIV和iv在每个时期对流感的保护程度:•2003-04年至2008-09年:2009年甲型H1N1流感大流行之前。•2010-11至2016-17:2009年大流行之后和改进LAIV毒株选择程序之前。•2017-18至2022-23:经过改进的LAIV菌株选择过程后。然后,研究人员使用了两种不同类型的荟萃分析,将来自多个研究的结果结合在一起,以创建LAIV和iv的VE的单一结果或概要估计,以帮助了解这两种类型的疫苗对任何流感疾病以及由特定流感病毒(例如甲型H1N1流感、甲型H3N2流感和乙型流感)引起的流感疾病的保护程度。•随机效应荟萃分析用于估计绝对疫苗有效性(aVE)——这是一种衡量疫苗与未接种疫苗相比如何预防疾病的措施。•使用网络荟萃分析来估计相对疫苗有效性(rVE)——这是一种疫苗与另一种疫苗相比对一种疾病的保护程度的度量。与iv相比,估计LAIV的rVE。所有aVE和rVE的总结估计都是根据它们的95%置信区间来解释的,这是一个值范围,表明研究人员对估计的确信程度,这意味着如果研究重复100次,真实结果将落在该范围内95次。本综述的主要结果是什么?本综述检查了北半球冬季流感季节国家的109项研究。结果表明,与未接种疫苗相比,LAIV和iv对任何流感疾病的有效性相似,在每个时间段的aVE均约为50%。 rVE估计显示,在2010-11年和2016-17年流感季节期间,LAIV在预防甲型H1N1流感疾病方面的效果不如iv (rVE=-46%; 95%置信区间:-57%至-33%)。•在2017-18流感季对LAIV毒株选择过程进行改进后,两种疫苗在2017-18和2022-23年间对甲型H1N1流感疾病的保护水平相似(rVE=10%; 95%置信区间:-35%至87%)。•在同一时期,LAIV和iv在预防甲型流感病毒感染方面同样有效(rVE=7%; 95%可信区间:-15%至33%)。•在改进的菌株选择过程后,LAIV对任何乙型流感病毒的疾病都比IIV更有效(rVE=196%; 95%置信区间:73%至406%)。这些结果意味着什么?这些发现表明,LAIV和iv对18岁以下儿童和青少年预防任何流感疾病提供类似的保护,接种任何流感疫苗都将提供预防流感疾病的保护。谁应该读这篇摘要?本摘要适用于考虑为孩子接种流感疫苗的父母、在医疗实践中不专门研究流感但为人们接种流感疫苗的医疗保健专业人员以及希望了解流感疫苗提供保护水平的个人。谁赞助了这项研究和简单的语言总结?这项研究和这个简单的语言总结都是由阿斯利康赞助的。
{"title":"Real-world Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children and Adolescents from 2003 to 2023: a Plain Language Summary of Publication.","authors":"Anke L Stuurman, Joshua Enxing, Aura V Gutiérrez, Christen M Gray, Ingrid T Sepúlveda-Pachón, Egbe Ubamadu, Allyn Bandell, Sylvia Taylor, Georges El Azzi, Wilhelmine Meeraus","doi":"10.1177/20499361251390680","DOIUrl":"https://doi.org/10.1177/20499361251390680","url":null,"abstract":"&lt;p&gt;&lt;p&gt;What is this summary about? This is a plain language summary describing the results of a systematic literature review and meta-analysis originally published in &lt;i&gt;Expert Review of Vaccines&lt;/i&gt; in July 2025. Children and adolescents are an important group for &lt;b&gt;influenza&lt;/b&gt; &lt;b&gt;vaccination&lt;/b&gt; because they play a major role in spreading &lt;b&gt;influenza&lt;/b&gt; viruses to others and are often hospitalized due to &lt;b&gt;influenza&lt;/b&gt;. &lt;b&gt;Live attenuated influenza vaccines (LAIV)&lt;/b&gt; and &lt;b&gt;inactivated &lt;b&gt;influenza&lt;/b&gt; vaccines (IIV)&lt;/b&gt; are two different types of &lt;b&gt;influenza&lt;/b&gt; &lt;b&gt;vaccine&lt;/b&gt; that are used to protect children and adolescents from &lt;b&gt;influenza&lt;/b&gt; illness. This review looked at how well LAIV and IIV provided protection against &lt;b&gt;influenza&lt;/b&gt; between 2003 (when LAIV was first available) and 2023 in children and adolescents under 18 years of age. Why was this review done? &lt;b&gt;Influenza&lt;/b&gt; viruses can change rapidly in ways that affect how well vaccines work in a particular &lt;b&gt;&lt;b&gt;influenza&lt;/b&gt; season&lt;/b&gt;. When this happens, &lt;b&gt;influenza&lt;/b&gt; vaccines may not provide good protection because they take many months to produce, with development starting about 6 months before the &lt;b&gt;influenza&lt;/b&gt; season begins. The specific versions of &lt;b&gt;influenza&lt;/b&gt; viruses, or strains, used to make vaccines change from year to year based on recommendations from &lt;b&gt;The World Health Organization&lt;/b&gt;. Public health bodies such as the United States' 'Advisory Committee on Immunization Practices' (US ACIP) and the United Kingdom's 'Joint Committee on &lt;b&gt;Vaccination&lt;/b&gt; and Immunisation' also publish recommendations on which vaccines should be used for the upcoming &lt;b&gt;influenza&lt;/b&gt; season on their respective websites and will update these recommendations for the next &lt;b&gt;influenza&lt;/b&gt; season if studies show that a particular &lt;b&gt;vaccine&lt;/b&gt; isn't providing enough protection. For this reason, &lt;b&gt;influenza&lt;/b&gt; vaccines can lose their recommendation for use or other vaccines may be recommended instead for use in select groups. For example, the US ACIP stopped recommending LAIV for the 2016-17 and 2017-18 &lt;b&gt;influenza&lt;/b&gt; seasons after some US-based studies showed it didn't protect well against the &lt;b&gt;influenza&lt;/b&gt; A (H1N1) &lt;b&gt;virus&lt;/b&gt; following the 2009 &lt;b&gt;influenza&lt;/b&gt; A (H1N1) pandemic. However, an updated LAIV was developed that improved on the &lt;b&gt;strain selection&lt;/b&gt; process and contained a replacement &lt;b&gt;influenza&lt;/b&gt; A (H1N1) strain. This led to LAIV being recommended by the committee again for the 2018-2019 &lt;b&gt;influenza&lt;/b&gt; season, and LAIV has continued to be recommended by the committee in its seasonal &lt;b&gt;vaccine&lt;/b&gt; guidance each year since 2019. The researchers carried out this review to look at how well LAIV and IIV protected against &lt;b&gt;influenza&lt;/b&gt; in children and adolescents in &lt;b&gt;real-world settings&lt;/b&gt; (e.g. outside clinical trials) since LAIV was first approved in 2003. How was this review carried out? The researchers found studies of LAIV and IIV ","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251390680"},"PeriodicalIF":3.4,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12541152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145356362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Therapeutic Advances in Infectious Disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1